Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D receptor activator, on arterial stiffness and osteopontin, a marker of atherosclerosis, in hypertensive patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
|
29305902 |
2020 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FFC displayed increased atherosclerosis and gene expression of inflammatory markers, including vascular cell adhesion molecule 1 (VCAM-1), cluster of differentiation 68 (CD68), matrix metalloproteinase 9 (MMP9), cathepsin K (CTSK) and secreted phosphoprotein 1 (SPP1) compared to Control and DNO (all, p < 0.05).
|
31004968 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
OPN identifies progression of atherosclerosis in persons free of ASCVD at baseline and may be a useful predictive tool to guide ASCVD prevention management.
|
30711632 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression.
|
31642412 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we focused on the role of osteopontin (OPN) as biomarker of subclinical atherosclerosis associated with SLE.
|
30767212 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies showed that key proteins of bone metabolism, such as osteoprotegerin (OPG) and osteopontin (OPN), are also involved in vascular atherosclerosis and calcifications.
|
30791743 |
2019 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating Osteopontin (OPN) levels have been also shown to have a potential role in the development of atherosclerosis.
|
31036794 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
OPN underlies several cardiovascular pathologies, including atherosclerosis and cardiac adverse remodeling.
|
30897705 |
2019 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phosphoprotein 1 (osteopontin) gene (rs4754) affects markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus.
|
28990744 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to test the hypothesis that OPN could be a potential marker for micro-vascular complications in children and adolescents with T1DM and we assessed its relation to carotid and aortic intima media thickness (CIMT and AIMT) as non-invasive index for subclinical atherosclerosis.
|
29687557 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) has been demonstrated to participate in the occurrence of atherosclerosis, inflammation, as well as the adhesion and migration of cells.
|
28978514 |
2018 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Herein, we show that teniposide protected SMC phenotype switching during atherosclerosis by enhancing expression of smooth muscle α-actin (SMA) while reducing osteopontin (OPN) expression in aortic lesion plaques.
|
30409428 |
2018 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, restoring Hes-1 expression and inhibiting OPN expression may be a promising strategy to prevent vulnerable plaque formation in patients with atherosclerosis.
|
28420872 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also revealed a NR6A1-CREB-SPP1 axis that serves as a regulatory mechanism for atherosclerosis and restenosis.
|
26546462 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence from several genetic mouse models suggests that OPN is an enhancer of atherosclerosis.
|
25128758 |
2014 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-derived osteopontin may contribute to inflammation in smokers, and may also contribute to atherosclerosis and cardiovascular disease-related processes.
|
22978720 |
2012 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NPP1 and OPN expression levels positively correlated with the degree of plaque calcification (R= 0.54, P= 0.00019 and R= 0.46, P= 0.017, respectively) and with risk factors of atherosclerosis.
|
20015201 |
2011 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Haplotype analysis revealed a genetic influence of osteopontin on large artery atherosclerosis.
|
18317949 |
2008 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) is a proinflammatory cytokine implicated in the chemoattraction of monocytes and the development of atherosclerosis.
|
17360982 |
2007 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) is a proinflammatory mediator involved in tissue remodeling that plays a role in atherosclerosis and diabetes.
|
17595250 |
2007 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The OPN and MCP-1 genes, coding for 2 cytokines with known roles in atherosclerosis, may contribute to increased carotid IMT and warrant further study.
|
16741188 |
2006 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin expression is related to urinary stone formation and several diseases associated with calcification such as atherosclerosis, breast cancer, and meningioma.
|
12142743 |
2002 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
From these observations, we concluded that pure atmospheric pressure directly promotes an expression of OPN in HASMC, with these results also suggesting that high blood pressure-mediated mechanical compression is involved in the process of atherosclerosis and remodeling via OPN expression in HASMC.
|
11327728 |
2001 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As OPN mRNA-expressing macrophages surrounded the atheromatous plaques, and as the level of OPN mRNA expression increased as atherosclerosis advanced, it is possible that OPN plays a role in the calcification of atheromatous plaques.
|
8213995 |
1993 |